Background: Lipid-lowering agents, particularly statins, have been central to the prevention of cardiovascular events in patients at high risk for coronary artery disease (CAD). While the short-term benefits of statins are well-documented, the long-term impact on morbidity and mortality, as well as its role in the prevention of recurrent cardiovascular events, remain subjects of ongoing research. Objective: This study aims to assess the long-term outcomes of lipid-lowering therapy in a cohort of patients with established cardiovascular disease, focusing on mortality, recurrent cardiovascular events, and overall quality of life. Methods: A multicenter, randomized, double-blind trial was conducted involving 2,500 patients with a history of myocardial infarction (MI) or stroke. Participants were randomly assigned to receive either a high-dose statin regimen (atorvastatin 40 mg) or placebo. The primary endpoints included all-cause mortality, cardiovascular mortality, and the occurrence of major cardiovascular events (myocardial infarction, stroke, or coronary revascularization) over a follow-up period of 10 years. Secondary outcomes evaluated quality of life (QoL) using standardized questionnaires, including the SF-36. Results: After 10 years of follow-up, the statin group demonstrated a 22% reduction in allcause mortality (p = 0.03) and a 35% reduction in cardiovascular mortality (p = 0.01) compared to the placebo group. Additionally, there was a significant reduction in major cardiovascular events by 29% (p = 0.02). No significant differences were observed in quality of life between groups, although statin use was associated with a modest increase in muscle-related side effects (p = 0.04). Conclusion: Long-term use of lipid-lowering agents, particularly statins, significantly reduces mortality and recurrent cardiovascular events in patients with established cardiovascular disease. This supports the ongoing use of statins as a cornerstone in secondary cardiovascular prevention, although attention to side effects, especially muscle-related symptoms, is warranted.